Two Novel Fibrillin-2 Mutations in CongenitalContractural Arachnodactyly

Susan Belleh,1 Guimei Zhou,1 Mei Wang,1 Vazken M. Der Kaloustian,3 Roberta A. Pagon,4 andMaurice Godfrey,1,2*1Center for Human Molecular Genetics, University of Nebraska Medical Center, Omaha, Nebraska2Department of Pediatrics, University of Nebraska Medical Center, Omaha, Nebraska3F. Clarke Fraser Clinical Genetics Unit, Division of Medical Genetics, The Montreal Children’s Hospital, McGillUniversity, Montreal, Quebec, Canada

4University of Washington School of Medicine, Division of Medical Genetics, Seattle, Washington

Congenital contractural arachnodactyly(CCA) is an autosomal dominant connectivetissue disorder, comprising marfanoid hab-itus, flexion contractures, severe kyphosco-liosis, abnormal pinnae, and muscular hypo-plasia. It is now known that mutations inthe gene encoding fibrillin-2 cause CCA. In-terestingly, mutations described to datecluster in the fibrillin-2 region homologousto the so-called neonatal Marfan syndromeregion of fibrillin-1. Thus, it has been hy-pothesized that the relative infrequency ofCCA compared with the Marfan syndrome isdue to the limited region of the gene tar-geted for mutations. In support of the abovehypothesis, we report here the finding oftwo additional FBN2 mutations in CCA,C1141F (exon 26) and C1252W (exon 29). Inaddition, a new 3* UTR polymorphism is alsodescribed. Am. J. Med. Genet. 92:7–12, 2000.© 2000 Wiley-Liss, Inc.

KEY WORDS: Beal’s syndrome; congenitalcontractural arachnodac-tyly; mutation; fibrillin-2;polymorphism

INTRODUCTION

The long quest to identify the genetic basis of theMarfan syndrome (MFS) ended in 1991 with the dis-

covery of the fibrillin gene on chromosome 15 (Fib15/FBN1)[Lee et al., 1991]. Serendipitously, a secondfibrillin gene that mapped to chromosome 5 was alsoidentified (Fib5/FBN2) [Lee et al., 1991]. The completeamino acid sequences of FBN1 and FBN2 have nowbeen published [Zhang et al., 1994; Pereira et al.,1993]. Genetic linkage analyses linked FBN2 to con-genital contractural arachnodactyly (CCA) [Tsipouraset al., 1992; Lee et al., 1991]. The phenotype of CCAoverlaps that of MFS [Hecht and Beals, 1972; Epsteinet al., 1968; Beals and Hecht, 1971]. CCA is an auto-somal dominant trait and sporadic cases are also ob-served [Lowry and Guichon, 1972; Bjerkreim et al.,1976; Beals and Hecht, 1971]. The incidence of CCA isnot known but appears to be less frequent than theMarfan syndrome. Individuals with CCA typicallyhave a marfanoid habitus, flexion contractures, severekyphoscoliosis, abnormal pinnae, and muscular hypo-plasia. Unlike MFS, CCA is associated with a normallifespan.

Numerous FBN1 mutations have been identified.These result in a wide range of findings: relatively mildskeletal abnormalities [Milewicz et al., 1995], ectopialentis [Kainulainen et al., 1994; Lonnqvist et al., 1994],late onset aortic aneurysms [Francke et al., 1995], neo-natal Marfan syndrome [Wang et al., 1995, 1997;Milewicz and Duvic, 1994; Kainulainen et al., 1994],and classical Marfan syndrome [for review, see Dietzand Pyeritz, 1995]. However, to date, only nine FBN2mutations have been identified in patients with CCA[Babcock et al., 1998; Park et al., 1998; Maslen et al.,1997; Putnam et al., 1995, 1997; Wang et al., 1996].Interestingly, all of these FBN2 mutations occur in arather limited region of FBN2. The analogous region inFBN1 is the so-called “neonatal Marfan region” wheremost mutations that cause the most severe form of theMarfan syndrome are found [Kainulainen et al., 1994].Here we describe two novel cysteine mutations: a T toG transversion at position 3756, resulting in a Cys1252 Trp change, and a G to T transversion at position3422, resulting in a Cys 1141 Phe substitution. Both ofthese mutations are found within the exon 24 to 34region. In addition, a 38 UTR polymorphism was de-

Grant sponsor: American Heart Association, Heartland Affili-ate; Grant number: 9807991S; Grant sponsor: March of DimesBirth Defects Foundation; Grant number: FY98-0522; Grantsponsor: National Marfan Foundation, USA; Grant sponsor:American Heart Association, National Center.

*Correspondence to: Dr. Maurice Godfrey, University of Ne-braska Medical Center, 985430 Nebraska Medical Center,Omaha, NE 68198-5430. E-mail: mgodfrey@unmc.edu

Received 19 July 1999; Accepted 26 January 2000

American Journal of Medical Genetics 92:7–12 (2000)

© 2000 Wiley-Liss, Inc.

tected in one of these patients. Population studiesshowed the presence of this polymorphism in 9 of 150chromosomes (6.0%).

MATERIALS AND METHODSPatient Samples

Patient 1 (CF1347) is an 8-year-old girl, born to non-consanguineous parents of French Canadian origin(Figs. 1, 2). At the time of her birth, the mother was 36years old and the father 37. Delivery was by repeatcesarean section. The birth weight was 3,050 g, birthlength was 49 cm, and birth head was circumference32.5 cm. Apgar scores were 8 and 9 at 1 and 5 min,respectively.

During this pregnancy, the mother had some vaginalbleeding in the first trimester and hypertension duringthe last trimester; otherwise the pregnancy was un-eventful. An older sister and an older brother arehealthy. Another sister, born 5 years earlier, died atthe age of 1 year of congenital cardiac anomalies. Thefamily history is otherwise non-contributory.

At the age of 2 months, during a genetics consulta-tion, she was found to have a cleft palate, low-set earswith abnormal folds of the pinnae, orbital hypertelor-

ism, micrognathia, single palmar creases bilaterally,and limited joint movements at the elbows, knees, andhips. Based on these findings, the diagnosis of CCAwas made.

Results of blood karyotype, renal echography, radi-ography of the chest and abdomen, and an electroen-cephalography were normal. She had been operated onfor her cleft palate at the age of 1 year. Her psychomo-tor development and school performance are normal.

At 8 years, her height was 124 cm (around the 45thcentile), her weight was 23 kg (∼30th centile), and herhead circumference was 51.5 cm (50th centile). The pal-ate is high and narrow arched. The pinnae are“crumpled.” There is a mid-thoracic kyphoscoliosis.There is restriction to the extension of the thumbs atthe metacarpophalangeal joint. The extension at thedistal interphalangeal joints of the first to fourth fin-gers is also limited bilaterally. Mild pterygia are notedat the fingers and elbows, limiting their extension.Muscle mass below the knees is small with slight limi-tation of extension at both knees. A 2.9 × 2 cm cafe-au-lait spot is present on the right arm laterally and an-other one (2.5 × 0.8 cm) at the left lumbarparavertebral area. The rest of the physical findings,including a cardiac findings, are normal.

Patient 2 (CF1449) is a 14 7⁄12-year-old girl with tallstature, slender body habitus, arachnodactyly, campto-datyly, and progressive kyphoscoliosis. She had mild

Fig. 1. Patient CF 1347. A: Face at 3 years. B: Profile at 3 years. C: Leftelbow at 3 years (note contracture). D: Left ear at 3 years (note crumpledupper pinna). E: Hands at 3 years (note arachnodactyly and camptodac-tyly). F: Total body (note bandaged right hand after surgery for the camp-todactyly and also the thin legs below the knees.

Fig. 2. Patient CF 1347 at 8 years. A: Profile (note crumpled upperpinna). B: Face. C: Anterior aspect of lower extremities. (Note thin legsbelow knees). D: Lateral aspect of lower extremities.

8 Belleh et al.

mental retardation and mild spasticity. The patientwas born to her gravida 4 para 3 mother. Delivery wasat term. She was first evaluated in the medical geneticsclinic at age 3 4⁄12 years. She walked independently atage 18 months. At 3 4⁄12 years she had only four spokenwords, although receptive language was better thanexpressive language. IQ testing documented a verbalscore of 70, performance score was 61, and full scale IQwas 65.

Radiographs of the spine obtained at 2 1⁄2 years docu-mented anterior beaking of the vertebrae, mild scolio-sis, and loss of lumbar lordosis. At age 6 1⁄2 years, shebegan wearing a body brace for progressive scoliosis. Ina 10 month period, between 13 and 14 years, she expe-rience painless progression of her right thoracic scolio-sis between T5 and T11 from 52 to 65°. There was norelated neurological deficit. At 14 years of age, she un-derwent posterior spinal instrumental fusion from T4to T12 with Isola hooks; 3⁄16-inch instrumentation wasused because of “minimal soft tissue.” The post-operative residual right convex curve remained stablewith the apex at T8. Subsequent radiographs showedabnormal iliac bones and bilateral coxa valga.

At 2 1⁄2 years, her height was at the 50 to 75th centilebut increased to the 95th centile by 4 3⁄12 years. At 147⁄12 years, her height was 161.6 cm (50th centile),weight was 30.7 kg (< 5th centile). and her OFC was 51cm (< 2nd centile).

Physical examinations between the ages of 2 and 14years documented a round and flat face with a flatnasal root and upturned nose, inner canthal distance of2.8 cm and outer canthal distance 8.2 cm, no iridoden-esis, and slightly thickened helices of the ears, whichwere not crumpled. Both ears were 5.2 cm long. Herpalate was slightly narrow but not vaulted. Her teethwere normally positioned without dental crowding. Shehad no heart defects. Her arms were long and slenderwith decreased muscle mass. She lacked 15° of exten-sion at the elbows but had normal supination and pro-nation of her forearms. Her fingers were long and slen-der with prominence of the joints. On the right hand,she had marked fifth finger camptodactyly and mildflexion contractures of the other three digits but not thethumb. On the left hand, she had mild contractures ofthe index and middle finger and more significant con-tractures of the ring and little fingers. She had slenderlegs with reduced muscle mass, particularly in thecalves. She had a full range of motion at her knees. Herankles were hypermobile and her feet were long, nar-row, and pronated. Her toes were long and slenderwithout contractures. She had a stiff-legged gait withsevere intoeing. Her balance and strength were nor-mal, but her deep tendon reflexes were 3 plus at thebiceps, triceps, brachioradialis, and knees. She had un-sustained clonus at the ankles. She had no Babinskiresponses. Skin was normal without unusual pigmen-tation, striae, or laxity.

Chromosomes were normal (46,XX). A urine meta-bolic screen at 61⁄2 years of age showed no homocysteinebut did show increased amounts of taurine. A 3 mmpunch skin biopsy was obtained for fibrillin studiesfrom her arm at age 14 1⁄2 years.

The patient had two older sibs and one younger

brother. An older sib was also said to be developmen-tally delayed. The mother was never evaluated in thegenetics clinic but also was said to be developmentallydelayed. The parents were not known to be related toeach other. There were no other individuals in the fam-ily known or suspected to have similar medical prob-lems.

Extraction of Nucleic Acids

DNA. Extraction of DNA from dermal fibroblastswas carried out by incubating 5 × 106 cells in 200 ml oflysis buffer [10 mM Tris HCl (pH 8.0), 2 mM EDTA, 10mM NaCl, 5% sodium dodecyl sulfate (SDS), and 200mg/ml Proteinase K] at 55°C for 16 hr [Sambrook et al.,1989]. In all extractions, the aqueous DNA was recov-ered by using phenol/chloroform extractions and iso-propanol precipitation. The extracted DNA was sus-pended in a 10 mM Tris HCl (pH 7.4), 1 mM EDTA (pH8.0) solution and concentration and purity were as-sessed spectrophotometrically.

RNA. RNA was extracted from dermal fibroblastsby using established techniques [Chomczynski andSacchi, 1987]. Briefly, cells were lysed in situ in a gua-nidine thiocyanate buffer containing b-mercaptoetha-nol. RNA was extracted with phenol/chloroform, pre-cipitated with ethanol, and stored at −80°C prior touse.

cDNA Production

Production of cDNA from RNA was performed by us-ing a commercially available kit (Amersham, ArlingtonHeights, IL) according to the manufacturer’s protocol.

Polymerase Chain Reaction (PCR)

Amplification of the patients’ fibroblast cDNA wasperformed using 45 pairs of overlapping primers tocover the entire approximately 10 kb coding region.Following PCR amplification, the amplicons were sub-jected to heteroduplex analyses (see below). Heterodu-plex bands for patient CF1347 were found by usingprimers A and B and patient CF1449 heteroduplexbands were found by using primers C and D (Table I).A heteroduplex band was also found in two unrelatedpatients by using primers E and F. Amplification wasperformed for 30 cycles: denaturation at 94°C for 1 min,annealing for 2 min (temperature for each primer pairis indicated in Table I), and extension at 72°C for 30sec.

Heteroduplex Analyses

Amplified products were screened for the presence ofpossible mutations by using Mutation Detection En-hancement (MDE) (FMC Corp., Rockland, ME) gels. Inorder to maximize the formation of heteroduplexes,Ten microliters of PCR product was mixed with 2 ml ofgel loading buffer (50% sucrose, 0.6% xylene cyanol,and 0.6% bromophenol blue) and incubated at 95°C/3min, 75°C/5 min, 55°C/5 min, and 37°C for at least 5min and until all samples were loaded on the gel.Samples were resolved on 0.5× MDE gels at 800 V forapproximately 5 hr, according to manufacturer’s proto-col. After electrophoresis, gels were stained in a solu-

FBN2 Mutations in CCA 9

tion of 0.6× TBE, containing 1 mg/ml ethidium bromideand DNA visualized under UV light.

Nucleotide Sequencing

All PCR products were gel purified and sequenceddirectly as previously described [Wang et al., 1996] orsequenced by using an automated sequencer (AppliedBiosystems, Foster City, CA; Model 372A) in the coresequencing laboratory of the Eppley Institute of theUniversity of Nebraska Medical Center. Amplificationprimers were used as sequencing primers as well. Mu-tations were confirmed by sequencing genomic DNA.

RESULTS

Heteroduplex analyses of PCR amplifications of 45overlapping FBN2 cDNA primer pairs showed only oneoccurrence of heteroduplex formation for each of pa-tients CF1347 and CF1449. The heteroduplex changesfor patients CF1347 and CF1449 were seen when

primer pairs A/B and C/D were used, respectively(Table I). Direct sequencing of the PCR productsshowed cysteine substitutions in one FBN2 allele ineach patient. Patient CF13478s mutation was in exon26, a G3422T transversion that resulted in a C1141Famino acid substitution. Neither of her parents har-bored the same change. Thus, the mutation was a denovo event. The mutation in patient CF1449 was inexon 29, a T3756G transversion that resulted in aC1252W amino acid substitution. Her parents were un-available for testing. Both mutations were confirmed inanalysis of genomic DNA. The position of the muta-tions along a schematic of the domain organization offibrillin-2 is shown in Figure 3.

While screening samples for FBN2 mutations, a het-eroduplex change, using primer pair E/F (Table I), wasfound in two unrelated patients. Sequencing analysisshowed that this was a three base deletion of nucleo-tides 8830 to 8832 in the 38 untranslated region. Popu-lation studies of 75 unrelated individuals [both CCA

TABLE I. Sequence of FBN2 cNDA Oligonucleotide Primers and the Pair’sRespective Annealing Temperature for PCR*

Primer SequenceAnnealing

temperature

A Sense 58 TCT CCT GAC CTC TGT GGC 38 55°CB Anti-Sense 58 TCA CAC ATT TTC CAT TTC TGC 38C Sense 58 TAT GAA GTA AAA AGC GAG AAC 38 53°CD Anti-Sense 58 ATC GTC TTT GGG GCA CAG 38E Sense 58 AGA GCA ATG AGG ATG ACT AC 38 55°CF Anti-Sense 58 CCA CGG TTG CCT TTG AGC 38

*Amplification conditions and patient specificities are noted in the text.

Fig. 3. Diagram of fibrillin-2 domain organization. The mutations in CCA patients previously identified are shown below the schematic, while thosereported here are shown within the EGF-like domain above. The peptide motifs are identified below the schematic.

10 Belleh et al.

patients (2/15) and unaffected controls (7/60)] showedthat 9 of 150 chromosomes (6.0%) contained that poly-morphic variant.

DISCUSSION

It is as yet unclear why mutations in FBN1, thatcause MFS and related disorders, appear to occur muchmore frequently than those in FBN2, even though theprimary structure of the coding regions of the twogenes are highly homologous. In part, it has been re-cently hypothesized, the difference may be due to thelimited region of FBN2 in which CCA mutations arefound [Park et al., 1998]. In addition, the usually ear-lier expression of FBN2 [Mariencheck et al., 1995;Zhang et al., 1995] allows speculation that its impor-tance in development is such that perturbations infibrillin-2 are poorly tolerated by a developing organ-ism. Our recent expansion of the CCA phenotype toinclude a severe/lethal form [Wang et al., 1996] sup-ports this possibility. Furthermore, the spectrum offibrillin-2 disease may continue to expand to includesome idiopathic cardiac septal defects, for example, sothat the mutation rates of the gamut of FBN1 andFBN2 microfibrillopathies will be similar. However, atpresent it appears that the systemic manifestations ofMFS are most frequently caused by substitutions forcysteine in precursor transforming growth factor b(TGF-b) like domains in fibrillin-1 [Dietz and Pyeritz,1995]. A similar pattern is beginning to emerge forfibrillin-2 mutations in CCA. Four fibrillin-2 mutationsreported to date (including here), that cause classicCCA, are cysteine substitutions. It is also of interestthat all reported FBN2 mutations occur in the longeststretch of TGF-b like domains, the region homologousto the “neonatal region” of FBN1 [Wang et al., 1996;Putnam et al., 1995; Kainulainen et al., 1994]. Thisobservation suggests that mutations in a limited regionof FBN2 cause the CCA phenotype. Thus, it is possiblethat mutations in other regions of FBN2 cause pheno-types that are not reminiscent of a “Marfan-like” dis-ease.

The phenotype of patient CF1347 was typical forCCA and her cysteine substitution occurred in exon 26.Patient CF1449 had a more unusual clinical course.Her mild developmental delay is probably unrelated tothe mutation in fibrillin-2. It is of interest that substi-tution of this cysteine (position 1252) had already beendescribed by Putnam et al. [1995]. However, in thatcase the substitution was a tyrosine residue.

Finally, we found a 38 UTR polymorphism in patientCF1347 and several other patient and controls. Thefrequency of this polymorphism in our population is6.0%. Studies in MFS have shown that individualswith relatively mild disease have a decreased expres-sion of the mutant FBN1 allele when compared to thewild-type allele in the same patient. Initial research inCCA indicated that the mutant allele was expressed atlevels higher than the wild-type allele [Putnam et al.,1997]. Therefore, we took advantage of this polymor-phism to examine the expression of the normal andmutant FBN2 alleles of patient CF1347. We found

equal steady-state expression of both normal and mu-tant alleles in cultured fibroblasts (data not shown).This finding is similar to what is seen in patients withclassic MFS having FBN1 mutations [Karttunen et al.,1996].

Exon skipping has been seen in about one third of thecases of CCA. This rate is much greater than the ob-served rate of mis-splicing in FBN1. In addition, in-stances of somatic and germline mosaicism have beendocumented [Putnam et al., 1997; Wang et al., 1996].This too appears rather high, given the relatively smallnumber of patients. The reasons for these observationsand the variability in expression of mutant versuswild-type alleles [Babcock et al., 1998; Park et al.,1998; Putnam et al., 1997] are unclear. Further studiesin more patients and the availability of animal modelswill facilitate the understanding of fibrillin-2 patho-genesis.

ACKNOWLEDGMENTS

M.G. is an Established Investigator of the AmericanHeart Association (funding was contributed in part bythe AHA Florida Affiliate). The expert graphics assis-tance of Mr. Joe Edwards is greatly appreciated.

REFERENCES

Babcock D, Gasner C, Francke U, Maslen C. 1998. A single mutation thatresults in an Asp to His substitution and partial exon skipping in afamily with congenital contractural arachnodactyly. Hum Genet 103:22–28.

Beals RK, Hecht F. 1971. Congenital contractural arachnodactyly, a heri-table disorder of connective tissue. J Bone Joint Surg 53-A:987–993.

Bjerkreim I, Skogland LB, Trygstad O. 1976. Congenital contracturalarachnodactyly. Acta Orthop Scand 47:250–253.

Chomczynski P, Sacchi S. 1987. Single-step method of RNA isolation byacid guanidinium thiocyanate-phenol-chloroform extraction. AnalytBiochem 162:156–159.

Dietz HC, Pyeritz RE. 1995. Mutations in the human gene for fibrillin-1(FBN1) in the Marfan syndrome and related disorders. Hum MolecGenet 4:1799–1809.

Epstein CJ, Graham CB, Hodgkin WE, Hecht F, Motulsky AG. 1968. He-reditary dysplasia of bone with kyphoscliosis, contractures, and abnor-mally shaped ears. J Pediatr 73:379–386.

Francke U, Berg MA, Tynan K, Brenn T, Liu W, Aoyama T, Gasner C,Miller DC, Furthmayr H. 1995. A Gly1127Ser mutation in an EGF-likedomain of the fibrillin-1 gene is a risk factor for ascending aortic an-eurysm and dissection. Am J Hum Genet 56:1287–1296.

Hecht F, Beals RK. 1972. “New” syndrome of congenital contracturalarachnodactyly originally described by Marfan in 1896. Pediatrics 49:574–579.

Kainulainen K, Karttunen L, Puhakka L, Sakai L, Peltonen L. 1994. Mu-tations in the fibrillin gene responsible for dominant ectopia lentis andneonatal Marfan syndrome. Nature Genet 6:64–69.

Karttunen L, Lonnqvist L, Godfrey M, Peltonen L, Syvanen AC. 1996. Anaccurate method for comparing transcript levels of two alleles or highlyhomologous genes: application to fibrillin transcripts in Marfan pa-tients’ fibroblasts. Genome Res 6: 392–403.

Lee B, Godfrey M, Vitale E, Hori H, Mattei M, Sarfarazi M, Tsipouras P,Ramirez F, Hollister DW. 1991. Linkage of Marfan syndrome and aphenotypically related disorder to two different fibrillin genes. Nature352:330–334.

Lonnqvist L, Child A, Kainulainen K, Davidson R, Puhakka L, Peltonen L.1994. A novel mutation of the fibrillin gene causing ectopia lentis.Genomics 19:573–576.

Lowry RB, Guichon VC. 1972. Congenital contractural arachnodactyly: a

FBN2 Mutations in CCA 11

syndrome simulating Marfan’s syndrome. Can Med Assoc J 107:531–533.

Mariencheck MC, Davis EC, Zhang H, Ramirez F, Rosenbloom J, GibsonMA, Parks WC, Mecham RP. 1995. Fibrillin-1 and fibrillin-2 show tem-poral and tissue-specific expression in developing elastic tissues. Con-nect Tiss Res 31:87–97.

Maslen C, Babcock D, Raghunath M, Steinmann B. 1997. A rare branch-point mutation is associated with missplicing of fibrillin-2 in a largefamily with congenital contractural arachnodactyly. Am J Hum Genet60:1389–1398.

Milewicz DM, Duvic M. 1994. Severe neonatal Marfan syndrome resultingfrom a de novo 3-bp insertion into the fibrillin gene on chromosome 15.Am J Hum Genet 54:447–453.

Milewicz DM, Grossfield J, Cao S, Kielty C, Covitz W, Jewett T. 1995. Amutation in FBN1 disrupts profibrillin processing and results in iso-lated skeletal features of the Marfan syndrome. J Clin Invest 95:2373–2378.

Park ES, Putnam EA, Chitayat D, Child A, Milewicz DM. 1998. Clusteringof FBN2 mutations in patients with congenital contractural arachno-dactyly indicates an important role of the domains encoded by exons 24through 34 during human development. Am J Med Genet 78:350–355.

Pereira L, D’Alessio M, Ramirez F, Lynch JR, Sykes B, Pangilinan T,Bonadio J. 1993. Genomic organization of the sequence coding for fibril-lin, the defective gene product in Marfan syndrome. Hum Molec Genet2:961–968.

Putnam EA, Park E, Aalfs CM, Hennekam RCM, Milewicz DM. 1997.Parental somatic and germ-line mosaicism for a FBN2 mutation andanalysis of FBN2 transcript levels in dermal fibroblasts. Am J HumGenet 60:818–827.

Putnam EA, Zhang H, Ramirez F, Milewicz DM. 1995. Fibrillin-2 (FBN2)

mutations result in the Marfan-like disorder, congenital contracturalarachnodactyly. Nature Genet 11:456–458.

Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning: a laboratorymanual. Cold Spring Harbor: Cold Spring Harbor Laboratory.

Tsipouras P, Del Mastro R, Sarfarazi M, Lee B, Vitale E, Child AH, God-frey M, Devereux RB, Hewett D, Steinmann B, Viljoen DL, Sykes B,Kilpatrick M, Ramirez F, the International Marfan Syndrome Collabo-rative Study. 1992. Linkage analysis demonstrates that Marfan syn-drome, dominant ectopia lentis, and congenital contractural arachno-dactyly are linked to the fibrillin genes on chromosmes 15 and 5. NEngl J Med 326:905–909.

Wang M, Clericuzio CL, Godfrey M. 1996. Familial occurrence of typicaland severe lethal congenital contractural arachnodactyly caused bymis-splicing of exon 34 of fibrillin-2 (FBN2). Am J Hum Genet 59:1027–1034.

Wang M, Price CE, Han J, Cisler J, Imaizumi K, Van Thienen MN, De-Paepe A, Godfrey M. 1995. Recurrent mis-splicing of fibrillin exon 32 intwo patients with neonatal Marfan syndrome. Hum Molec Genet 4:607–613.

Wang M, Wang J, Imaizumi K, Jones MC, Lamberti JJ, Burton BK, God-frey M. 1997. Three novel fibrillin mutations in exons 25 and 27: clas-sical versus neonatal Marfan syndrome. Hum Mutat 9:359–362.

Zhang H, Apfelroth SD, Hu W, Davis EC, Sanguineti C, Bonadio J,Mecham RP, Ramirez F. 1994. Structure and expression of fibrillin-2 anovel microfibrillar component preferentially located in elastic matri-ces. J Cell Biol 124:855–863.

Zhang H, Hu W, Ramirez F. 1995. Developmental expression of fibrillingenes suggests heterogeneity of extracellular microfibrils. J Cell Biol129:1165–1176.

12 Belleh et al.